Vascular calcification (VC) is associated with an increased cardiovascular morbimortality in chronic kidney disease (CKD). The prevalence of VC increases steadily through the stages of chronic kidney disease. Well-designed clinical trials are urgently needed to test the potential value of these biomarkers as a guide for interventions targeting VC now. This review gives a brief overview of the circulating biomarkers of vascular calcification in CKD patients.